PMID: 25764690Mar 15, 2015Paper

Direct-acting antiviral-resistant variant

Nihon rinsho. Japanese journal of clinical medicine
Michio Imamura, Kazuaki Chayama

Abstract

Recently, IFN-free NS5A inhibitor daclatasvir and protease inhibitor asunaprevir combination treatment was approved for genotype 1b HCV-infected patients who were ineligible or who failed to respond to previous therapies. NS5A inhibitor-resistant variants occasionally exist in HCV-infected patients who have never been exposed to direct-acting antivirals. In Japanese HCV genotype 1b-infected patients, the frequency of NS5A inhibitor-resistant variants is approximately 11-23 %. The phase 3 study of daclatasvir and asunaprevir combination therapy showed that more patients with NS5A 31 and/or 93 resistance-associated variants experienced virological failure. Preexisting NS5A inhibitor-resistant variants should be evaluated carefully before choosing the drugs.

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.